Circulating prostaglandin E2 concentrations and incidence of patent ductus arteriosus in preterm infants with respiratory distress syndrome
- PMID: 7432878
Circulating prostaglandin E2 concentrations and incidence of patent ductus arteriosus in preterm infants with respiratory distress syndrome
Abstract
In several species prostaglandin E2 (PGE2) appears to be the most important prostanoid to regulate patency of the ductus arteriosus. We measured the arterial plasma concentration of PGE2 in 29 premature infants (17 with respiratory distress syndrome alone and 12 with respiratory distress syndrome and patent ductus arteriosus) to determine if there was an association between circulating PGE2 and patent ductus arteriosus. The PGE2 concentrations during the first two days after birth were higher than PGE2 concentrations after the third postnatal day (17.1 +/- 3.1 pg/ml, mean +/- SEM, n = 23, vs 6.12 +/- 0.63 pg/ml, n = 19, P < .005). By the third postnatal day, arterial concentrations were similar to adult venous values. There was no significant difference between the plasma PGE2 concentrations in the 12 infants with patent ductus arteriosus and the concentrations in the 17 infants who had no signs of patent ductus arteriosus. These findings do not support the hypothesis that an increased concentration of circulating PGE2 is the primary cause for the persistent patency of the ductus arteriosus in preterm infants with respiratory distress syndrome.
Similar articles
-
Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome.N Engl J Med. 1983 Mar 31;308(13):743-8. doi: 10.1056/NEJM198303313081303. N Engl J Med. 1983. PMID: 6828120 Clinical Trial.
-
Plasma prostaglandin E2 and F2 alpha in preterm infants: association with respiratory distress syndrome and patent ductus arteriosus.Prostaglandins Leukot Med. 1983 Apr;10(4):423-31. doi: 10.1016/0262-1746(83)90054-9. Prostaglandins Leukot Med. 1983. PMID: 6574525
-
Circulating prostaglandin E2 concentrations and patent ductus arteriosus in fetal and neonatal lambs.J Pediatr. 1980 Sep;97(3):455-61. doi: 10.1016/s0022-3476(80)80205-8. J Pediatr. 1980. PMID: 6902770
-
The relationship of symptomatic patent ductus arteriosus to respiratory distress in premature newborn infants.Clin Perinatol. 1987 Sep;14(3):621-33. Clin Perinatol. 1987. PMID: 3311542 Review.
-
Patent ductus arteriosus and respiratory outcome in premature infants.Biol Neonate. 2005;88(3):192-201. doi: 10.1159/000087582. Biol Neonate. 2005. PMID: 16210841 Review.
Cited by
-
Ibuprofen Versus Indomethacin for Medical Closure of the Patent Arterial Duct: A Pooled Analysis by Route of Administration.Cureus. 2015 Jun 4;7(6):e274. doi: 10.7759/cureus.274. eCollection 2015 Jun. Cureus. 2015. PMID: 26180698 Free PMC article.
-
Patent ductus arteriousus in the premature neonate: current concepts in pharmacological management.Paediatr Drugs. 1999 Apr-Jun;1(2):81-92. doi: 10.2165/00128072-199901020-00002. Paediatr Drugs. 1999. PMID: 10937444 Review.
-
Mannheimer lecture.Pediatr Cardiol. 1982;3(1):71-6. doi: 10.1007/BF02082336. Pediatr Cardiol. 1982. PMID: 6760143 Clinical Trial. No abstract available.
-
The pharmacological treatment of patent ductus arteriosus. A review of the evidence.Drugs. 1989 Aug;38(2):249-66. doi: 10.2165/00003495-198938020-00006. Drugs. 1989. PMID: 2670518 Review.